Compare AOUT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOUT | CALC |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.7M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | AOUT | CALC |
|---|---|---|
| Price | $8.72 | $5.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $12.50 | ★ $16.00 |
| AVG Volume (30 Days) | 73.5K | ★ 96.2K |
| Earning Date | 03-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $207,348,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $6.26 | $1.42 |
| 52 Week High | $17.91 | $7.20 |
| Indicator | AOUT | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 53.90 |
| Support Level | $7.65 | $5.05 |
| Resistance Level | $9.99 | $5.71 |
| Average True Range (ATR) | 0.57 | 0.72 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 41.45 | 30.55 |
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.